FindTrial
Sign In

An observational study of the efficacy and safety of immune checkpoint inhibitor monotherapy in the treatment of patients with Child-Pugh class B intermediate and advanced hepatocellular carcinoma

An observational study of the efficacy and safety of immune checkpoint inhibitor monotherapy in the treatment of patients with Child-Pugh class B intermediate and advanced hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111227
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-10-30
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Case series:No

Sponsors

The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient is at least 18 years old; 2. The patient was pathologically diagnosed with hepatocellular carcinoma through liver biopsy and received dual immunotherapy with anti-tumor drugs. 3. The Child-Pugh classification is B (8/9) grade; 4. ECOG PS score: 0-1 point; 5. There is at least one measurable target lesion according to the mRECIST standard.

Exclusion criteria

Exclusion criteria: 1. There are any serious comorbidities of other vital organs; 2. The patient has a history or current concurrent presence of other malignant tumors; 3. Those with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Objective relief rate;—

Secondary

MeasureTime frame
Overall survival;Progression free survival;—

Countries

China

Contacts

Public ContactJiamin Cheng

The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

chengjiamin300@163.com+86 10 6639 9073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026